Oramed Pharmaceuticals Competitors
| ORMP Stock | USD 3.85 0.01 0.26% |
Oramed Pharmaceuticals and Connect Biopharma Correlation Details
Very good diversification
Oramed Pharmaceuticals currently posts a 0.04 correlation with Connect Biopharma, indicating a Very good diversification relationship for the active sample. This chart measures the degree of risk overlap between Oramed Pharmaceuticals and Connect Biopharma.
Mean reversion in Oramed Pharmaceuticals' price occurs when temporary dislocations correct back toward its historical intrinsic value estimate. This tendency of Oramed Pharmaceuticals' price to converge to an average value over time is called mean reversion.
Oramed Pharmaceuticals Competition Correlation Matrix
Reviewing how Oramed Pharmaceuticals moves relative to competing stocks can show whether peer exposure is reducing portfolio risk or simply repeating the same market bet. The business currently sits in the Healthcare sector and the Biotechnology industry. In practical terms, lower correlation may offer better diversification while higher correlation may leave the portfolio more exposed to one shared driver.
Please upgrade your account to get full access to Macroaxis premium features
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Return momentum in Oramed Stock is more useful when tested against peer-relative fundamentals and risk. Without risk-adjusted context, short-term returns may appear stronger than the volatility required to achieve them would suggest. These indicators are quantitative in nature and measure volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| OVID | 4.13 | 0.83 | 0.18 | 1.47 | 4.16 | 11.30 | 22.69 | |||
| CNTX | 4.54 | 0.64 | 0.11 | -2.86 | 5.48 | 9.24 | 30.95 | |||
| CLNN | 4.24 | 0.33 | 0.06 | 0.21 | 5.07 | 9.44 | 22.42 | |||
| STTK | 3.10 | 0.92 | 0.30 | 1.66 | 2.57 | 7.82 | 23.94 | |||
| COYA | 2.79 | -0.02 | 0.00 | -0.01 | 0.00 | 6.70 | 19.44 | |||
| MGNX | 3.89 | 1.12 | 0.30 | 0.79 | 2.91 | 9.47 | 53.20 | |||
| IMA | 2.81 | -0.25 | 0.00 | -0.28 | 0.00 | 4.48 | 28.76 | |||
| IFRX | 3.99 | 0.74 | 0.17 | 0.40 | 3.88 | 7.23 | 40.01 | |||
| KLRS | 4.13 | -0.56 | 0.00 | -0.50 | 0.00 | 8.87 | 35.44 | |||
| CNTB | 4.70 | 0.17 | 0.03 | 0.41 | 6.03 | 9.23 | 27.88 |
Peer Comparison: Net Income
Net income is what remains after all costs — operating expenses, interest, taxes, and preferred dividends — are deducted from Oramed Pharmaceuticals's total revenue. The relationship between net income growth and revenue growth at Oramed Pharmaceuticals reveals whether margin expansion is driving earnings or whether top-line growth is being consumed by rising costs and financing charges.Compare Oramed Pharmaceuticals and related stocks such as Ovid Therapeutics, Context Therapeutics, and Clene Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OVID | -447 K | -447 K | -447 K | -447 K | -447 K | -13.2 M | -22.4 M | -64.8 M | -52 M | -59.3 M | -80.7 M | 122.8 M | -51.4 M | -52.3 M | -26.4 M | -17.4 M | -18.3 M |
| CNTX | -37.7 M | -37.7 M | -37.7 M | -37.7 M | -37.7 M | -37.7 M | -37.7 M | -24.6 M | -7.5 M | -7.5 M | 6.6 M | -10.5 M | -14.8 M | -24 M | -26.7 M | -36.1 M | -34.3 M |
| CLNN | -2.4 K | -2.4 K | -2.4 K | -2.4 K | -2.4 K | -2.4 K | -2.4 K | -2.4 K | -277.3 K | -16.2 M | -19.3 M | -9.7 M | -29.9 M | -49.5 M | -39.4 M | -26.2 M | -27.5 M |
| STTK | -7.4 M | -7.4 M | -7.4 M | -7.4 M | -7.4 M | -7.4 M | -7.4 M | -7.4 M | -7.4 M | -24 M | -35.4 M | -45 M | -100.6 M | -87.3 M | -75.4 M | -48.8 M | -51.2 M |
| COYA | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -1.1 M | -4.9 M | -12.2 M | -8 M | -14.9 M | -21.2 M | -20.2 M |
| MGNX | 6.7 M | 6.7 M | 8.4 M | -260.8 K | -38.3 M | -20.1 M | -58.5 M | -19.6 M | -171.5 M | -151.8 M | -117.8 M | -190.9 M | -120 M | -9.1 M | -67 M | -74.6 M | -78.4 M |
| IMA | -40.9 M | -40.9 M | -40.9 M | -40.9 M | -40.9 M | -40.9 M | -40.9 M | -40.9 M | -40.9 M | -16.8 M | -44.3 M | -34.1 M | -68.8 M | -68.2 M | -36.6 M | -45.3 M | -47.6 M |
| IFRX | -4.9 M | -4.9 M | -4.9 M | -4.9 M | -4.9 M | -4.9 M | -8.9 M | -24.2 M | -29.8 M | -59.6 M | -38.7 M | -53.9 M | -31 M | -42.7 M | -46.1 M | -43.8 M | -46 M |
| KLRS | -2.4 M | -2.4 M | -2.4 M | -2.4 M | -2.4 M | -2.4 M | -2.4 M | -2.4 M | -2.4 M | -23.8 M | -69.8 M | -172 M | -15.5 M | -14.7 M | -58.8 M | -43.4 M | -45.6 M |
| CNTB | -24.5 M | -24.5 M | -24.5 M | -24.5 M | -24.5 M | -24.5 M | -24.5 M | -24.5 M | -24.5 M | -24.5 M | -119.4 M | -202.3 M | -118.1 M | -62.1 M | -15.6 M | -55.5 M | -58.3 M |
Oramed Pharmaceuticals Competitive Analysis
Oramed Pharmaceuticals competes directly with Ovid Therapeutics, Context Therapeutics, and Clene, and the financial data points to clear areas of divergence. On scale alone, Oramed Pharmaceuticals' 155.7 M valuation and 2.0 M revenue define its weight class. The company converts revenue to profit at a 3202.50% rate and delivers 37.10% on shareholder equity. Oramed Pharmaceuticals keeps more of each revenue dollar with a 3202.50% margin versus -240.13% at Ovid Therapeutics. Market capitalization diverges sharply here: 207.6 M versus 155.7 M, giving Context Therapeutics a clear size advantage. On equity returns, Oramed Pharmaceuticals earns 37.10% compared to -1738.36% at Clene.| Better Than Average | Worse Than Peers | View Performance Chart |
Oramed Pharmaceuticals Competition Peer Performance Charts
How to Analyze Oramed Pharmaceuticals Against Peers
Oramed Pharmaceuticals' peer analysis compares Oramed Pharmaceuticals with related companies to put valuation, quality, and risk metrics in context. This establishes whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Oramed Pharmaceuticals trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Oramed Pharmaceuticals leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Oramed Pharmaceuticals' return on invested capital tops the peer average, meaning each dollar of capital is working harder here. Capex-to-depreciation ratios across Oramed Pharmaceuticals' competitors separate companies that are investing for growth from those in maintenance mode. Relative ranking may help frame which fundamentals deserve deeper follow-up. For peer comparison, Oramed Pharmaceuticals has a market cap of 155.72 M, profit margin of 32.03%.
Oramed Pharmaceuticals data is compiled from periodic company reporting and market reference feeds and standardized for comparability.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board